Peer-influenced content. Sources you trust. No registration required. This is HCN.

Contact Lens SpectrumPharmaceutically Enhancing Specialty Lens Outcomes

How therapeutic drugs can aid in enhancing the results of specialized lenses.

In an era where both specialty lenses and therapeutics have seen significant advancements, physicians must employ an integrative approach to improve patient outcomes. This involves not only prescribing the most appropriate specialty lenses but also understanding the influence of various factors like lid position, dry eye, pupil size, allergies, and presbyopia that may affect lens wear. By leveraging targeted pharmaceutical interventions, physicians can offer a holistic treatment strategy for a range of ocular and corneal conditions.

HCN Medical Memo
To physicians focused on providing tailored vision solutions, the blend of specialty lens prescriptions and targeted pharmaceutical treatments represents a new frontier in patient care. By taking a holistic approach that considers multiple aspects—like lid positioning, dry eye symptoms, pupil size, and allergic reactions—physicians can significantly elevate the visual outcomes and comfort of their specialty lens wearers.

Key Points
  • Lid Position and Pharmaceuticals: A new pharmaceutical agent, 0.1% oxymetazoline, has been approved for age-related blepharoptosis and has shown improvements in both upper eyelid position and superior visual field.
  • Dry Eye Management: Applying a polyethylene glycol (PEG) polymer mixture improves lens comfort and tear breakup time (TBUT) in scleral lens wearers.
  • Pupil Size Dynamics: Brimonidine, an alpha-2 adrenergic agonist, can reduce pupil size and enhance vision quality in low-light conditions.
  • Allergy Considerations: Antihistamines like olopatadine and corticosteroids are available for allergic responses, and daily disposable lenses offer another avenue for patients with hypersensitivities.
  • Advancements in Presbyopia Treatment: Therapeutics like pilocarpine 1.25% are emerging as aids in presbyopia treatment by reducing pupil size and enhancing depth of focus.

According to the American Academy of Ophthalmology, about 4.88 million Americans age 50 and older are affected by dry eye.

Additional Points
  • Special Considerations for Multifocal Lenses: Patients with severe ptosis may experience reduced optical quality, making eyelid position a critical consideration.
  • Treatment Options for Allergies: Practitioners should also consider peroxide-based disinfecting systems for specialty lens wearers.
  • Presbyopic Advancements: Other molecules are being studied for pupil constriction to improve near vision, such as aceclidine and carbachol.

More in Dry Eye Disease (DED)

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form